PRADAXA Capsules is a direct thrombin inhibitor indicated:
• To reduce the risk of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation
• For the treatment of deep venous thrombosis (DVT) and pulmonary
embolism (PE) in adult patients who have been treated with a parenteral
anticoagulant for 5-10 days
• To reduce the risk of recurrence of DVT and PE in adult patients who have
been previously treated
• For the prophylaxis of DVT and PE in adult patients who have undergone
hip replacement surgery
• For the treatment of venous thromboembolic events (VTE) in pediatric
patients 8 to less than 18 years of age who have been treated with a
parenteral anticoagulant for at least 5 days
• To reduce the risk of recurrence of VTE in pediatric patients 8 to less than
18 years of age who have been previously treated
